Corvus Pharmaceuticals

CRVSNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$1.045 B

$12.42 -1.11%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$15.3M

Loss-making

Shares outstanding

84,120,944

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#151MoonLake ImmunotherapeuticsMLTX$1.07B
#152Jade BiosciencesJBIO$1.06B
#153Corvus PharmaceuticalsCRVS$1.04B
#154Amphastar PharmaceuticalsAMPH$1.04B
#155Janux TherapeuticsJANX$1.04B

What if Corvus Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.3T

$359,887.24

Per share 28,976× higher

Bitcoin $1.72T

$20,444.42

Per share 1,646× higher

Nvidia $5.48T

$65,142.61

Per share 5,245× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Corvus Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.